Challenges in replacement therapy of hypothyroidism: everyday practice and perspectives

Cover Page

Abstract


Проблема заместительной терапии гипотиреоза, распространенность которого в общей популяции достигает 3,7% [1], так или иначе касается любого заболевания щитовидной железы (ЩЖ), поскольку в клинической практике большинство из них гипотиреозом так или иначе заканчивается, как самопроизвольно, так и вследствие врачебных вмешательств. На первый взгляд, заместительная терапия гипотиреоза достаточно проста и в соответствии с многочисленными клиническими рекомендациями подразумевает ежедневный прием L-T4 под периодическим контролем уровня тиреотропного гормона (ТТГ). Тем не менее, даже если не считать такого важного момента, как приверженность пациента к правильному лечению, здесь есть много дискуссионных вопросов и сложностей, решение которых, по мнению автора этого обзора, и представляет перспективу в обсуждаемой области тиреоидологии.

About the authors

Email: walfad@mail.ru
doktor med. nauk, professor kafedry endokrinologii Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, zam. direktora FGBU Endokrinologicheskiy nauchnyy tsentr Minzdravsotsrazvitiya RF

References

  1. Aoki Y., Belin R.M., Clickner R. et al. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999–2002). Thyroid 2007; 17: 1211–1223.
  2. Larsen P.R., Silva J.E., Kaplan M.M. Relationships between circulating and intracellular thyroid hormones: physiological and clinical implications. Endocr. Rev. 1981; 2; 87–102.
  3. Fadeyev V.V., Morgunova T.B., Sytsh J.P., Melnichenko G.A. TSH and thyroid hormones concentrations in patients with hypothyroidism receiving replacement therapy with L-thyroxine alone or in combination with L-triiodthyronine. HORMONES 2005; 4 (2): 101–107.
  4. Saravanan P., Chau W.F., Roberts N. et al. Psychological well- being in patients on adequate doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin. Endocrinol. (Oxf.) 2002; 57; 577–585.
  5. Visser W.E., Friesema E.C., Visser T.J. Thyroid hormone transporters: the knowns and the unknowns. Mol. Endocrinol. 2011; 25: 1–14.
  6. Zhang J., Lazar M.A. The mechanism of action of thyroid hormones. Ann. Rev. Physiol. 2000; 62: 439–466.
  7. Ramadan W., Marsili A., Larsen P.R. et al. Type-2 iodothyronine 5-deiodinase in skeletal muscle of C57BL/6 mice. I. Identity, subcellular localization, and characterization. Endocrinology 2011; 152: 3082–3092.
  8. Galton V.A. The roles of the iodothyronine deiodinases in mammalian development. Thyroid 2005; 15: 823–834.
  9. Medina M.C., Molina J., Gadea Y. et al. The thyroid hormone-in- activating type III deiodinase is expressed in mouse and human β-cells and its targeted inactivation impairs insulin secretion. Endocrinology 2011; 152: 3717–3727.
  10. Huang S.A., Bianco A.C. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat. Clin. Pract. Endocrinol. Metab. 2008; 4: 148–155.
  11. Gullo D., Latina A., Frasca F. et al. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS One 2011; 6: e22552.
  12. Bianco A.C., Salvatore D., Gereben B. et al. Biochemistry, cellular and molecular biology and physiological roles of the iodothyronine selenodeiodinases. Endocr. Rev. 2002; 23: 38–89.
  13. Schneider M.J., Fiering S.N., Pallud S.E. et al. Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4. Mol. Endocrinol. 2001; 15: 2137–2148.
  14. Escobar-Morreale H.F., Obregón M.J., Escobar del Rey F., Morreale de Escobar G. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J. Clin. Invest. 1995; 96: 2828–2838.
  15. Andersen S., Bruun N.H., Pedersen K.M., Laurberg P. Biologic variation is important for interpretation of thyroid function tests. Thyroid 2003; 13: 1069–1078.
  16. Bianco A.C., Silva J.E. Cold exposure rapidly induces virtual saturation of brown adipose tissue nuclear T3 receptors. Am. J. Physiol. 1988; 255: 496–503.
  17. Dumitrescu A.M., Liao X.H., Abdullah M.S. et al. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nat. Gen. 2005; 37: 1247–1252.
  18. Schneider M.J., Fiering S.N., Thai B. et al. Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology 2006; 147: 580–589.
  19. Dayan C.M., Panicker V. Novel insights into thyroid hormones from the study of common genetic variation. Nat. Rev. Endocrinol. 2009; 5: 211–218.
  20. De Jong F.J., Peeters R.P., den Heijer T. et al. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J. Clin. Endocrinol. Metab. 2007; 92: 636–640.
  21. Crantz F.R., Silva J.E., Larsen P.R. Analysis of the sources and quantity of 3,5,3-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum. Endocrinology 1982; 110: 367–375.
  22. Canani L.H., Capp C., Dora J.M. et al. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2005; 90: 3472–3478.
  23. Dora J.M., Machado W.E., Rheinheimer J. et al. Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study and meta-analysis. Eur. J. Endocrinol. 2010; 163: 427–434.
  24. Guo T.W., Zhang F.C., Yang M.S. et al. Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of China. J. Med. Genet. 2004; 41: 585–590.
  25. Gumieniak O., Perlstein T.S., Williams J.S. et al. Ala92 type 2 deio- dinase allele increases risk for the development of hypertension. Hypertension 2007; 49: 461–466.
  26. Meulenbelt I., Min J.L., Bos S. et al. Identification of DIO2 as new susceptibility locus for symptomatic osteoarthritis. Hum. Mol. Genet. 2008; 17: 1867–1875.
  27. He B., Li J., Wang G. et al. Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2009; 33: 986–990.
  28. Torlontano M., Durante C., Torrente I. et al. Type 2 deiodinase polymorphism (Thr92Ala) predicts L-thyroxine dose to achieve target TSH levels in thyroidectomized patients. J. Clin. Endocrinol. Metab. 2008; 93: 910–913.
  29. Butler P.W., Smith S.M., Linderman J.D. et al. The Thr92Ala 5-type 2 de-iodinase gene polymorphism is associated with a delayed triiodothyronine secretion in response to the thyrotropin-releasing hormone-stimulation test: a pharmacogenomic study. Thyroid. 2011; 20: 1407–1412.
  30. Ng L., Lyubarsky A., Nikonov S.S. et al. Type 3 deiodinase, a thy- roidhormone-inactivating enzyme, controls survival and matura- tion of cone photoreceptors. // J. Neurosci. 2010; 30: 3347–3357.
  31. Mohacsik P., Zeold A., Bianco A.C., Gereben B. Thyroid hormone and the neuroglia: both source and target. J. Thyroid. Res. 2011; 2011: 215718.
  32. Dumitrescu A.M., Liao X.H., Best T.B. et al. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am. J. Hum. Genet. 2004; 74: 168–175.
  33. Sugiyama D., Kusuhara H., Taniguchi H. et al. Functional charac- terization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine. J. Biol. Chem. 2003; 278: 43489–43495.
  34. Van der Deure W., Appelhof B.C., Peeters R.P. et al. Polymorphism in the brain-specific thyroid hormone transporter OATP-C1 are associated with fatigue and depression in hypothyroid patients. Clin. Endocrinol. 2008; 69: 804–811.
  35. Canaris G.J., Manowitz N.R., Mayor G., Ridgway E.C. The Colorado thyroid disease prevalence study. Arch. Intern. Med. 2000; 28: 526–534.
  36. Katon W., Schulberg H. Epidemiology of depression in primary care. Gen Hosp. Psychiatry 1992; 14: 237–247.
  37. Paunkovic N., Paunkovic J., Pavlovic O., Paunovic Z. The significant increase in incidence of Graves' disease in eastern Serbia during the civil war in the former Yugoslavia (1992 to 1995). Thyroid. 1998; 8: 37–41.
  38. Louwerens M., Appelhof B.C., Verloop H. et al. Fatigue and fatigue- related symptoms in patients treated for different causes of hypothyroidism. Eur. J. Endocrinol. 2012; Sep (in press).
  39. Walsh J. P., Ward L. C., Burke V. et al. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J. Clin. Endocrinol. Metab. 2006; 91: 2624–2630.
  40. Подзолков А.В., Фадеев В.В. Оценка динамики показателей липидного спектра и ранних предикторов эндотелиальной дисфункции при первичным гипотиреозе в зависимости от уровня ТТГ в пределах референсного диапазона. Клин. и экспер. тиреоидол. 2010; 3: 54–59.
  41. Подзолков А.В., Фадеев В.В. Высоко- и низконормальный уровень ТТГ: клиническая картина, психоэмоциональная сфера и качество жизни пациентов с гипотиреозом. Клин. и экспер. тиреоидол. 2010; 4: 58–68.
  42. Bunevicius R., Kazanavicius G., Zalinkevicius R., Prange A.J. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. Engl. J. Med. 1999; 340: 424–429.
  43. Bunevicius R., Jakubonien N., Jurkevicius R. et al. Thyroxine vs. thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves’ disease. Endocrine 2002; 18: 129–133.
  44. Nygaard B., Jensen E.W., Kvetny J. et al. Effect of combination therapy with thyroxine (T4) and 3,5,3-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur. J. Endocrinol. 2009; 161: 895–902.
  45. Grozinsky-Glasberg S., Fraser A., Nahshoni E. et al. Thyroxine-tri- iodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J. Clin. Endocrinol. Metab. 2006; 91: 2592–2599.
  46. Garber J.R., Cobin R.H., Gharib H. et al. Clinical Practice Guidelines for Hypothyroidism in Adults: Co-sponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr. Pract. 2012; 11: 1–207.
  47. Wiersinga W., Duntas L., Fadeyev V. et al. The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. Eur. Thyroid. J. 2012; 1: 55–71.
  48. Фадеев В.В. По материалам клинических рекомендаций Европейской тиреоидной ассоциации по использованию комбинированной терапии L-T4 + L-T3 в лечении гипотиреоза. Клин. и экспер. тиреоидол. 2012; 2: 14–18.
  49. Fadeyev V.V., Morgunova T.B., Melnichenko G.A., Dedov I.I. Combined therapy with L-Thyroxine and L-Triiodothyronine compared to L-Thyroxine alone in the treatment of primary hypothyroidism. Hormones (Athens) 2010; 9: 245–252.
  50. Panicker V., Saravanan P., Vaidya B. et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J. Clin. Endocrinol. Metab. 2009; 94: 1623–1629.
  51. Hollowell J.G., Staehling N.W., Flanders W.D. et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 2002; 87: 489–499.
  52. Völzke H., Schmidt C.O., John U. et al. Reference levels for serum thyroid function tests of diagnostic and prognostic significance. Horm. Metab. Res. 2010; 42: 809–814.
  53. Фадеев В.В., Берковская М.А., Мельниченко Г.А. Результаты опроса эндокринологов по проблемам нарушения функции щитовидной железы. Клин. и экспер. тиреоидол. 2008; 2: 41–47.
  54. Свиридонова М.А., Фадеев В.В., Ильин А.В. Циркадианная и индивидуальная вариабельность уровня ТТГ и тиреоидных гормонов у лиц с субклиническим гипотиреозом. Клин. и экспер. тиреоидол. 2010; 3: 35–41.
  55. Свиридонова М.А., Ильин А.В., Фадеев В.В. Циркадианная и индивидуальная вариабельность уровня ТТГ у лиц, получающих заместительную терапию гипотиреоза. Клин. и экспер. тиреоидол. 2010; 4: 52–57.
  56. Свиридонова М.А., Ильин А.В., Фадеев В.В. Циркадианная вариабельность уровня ТТГ на фоне супрессивной терапии левотироксином. Клин. и экспер. тиреоидол. 2011; 1: 55–57.
  57. Stagnaro-Green A., Abalovich M., Alexander E. et al. Guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011; 21 (21): 1081–1125.
  58. Фадеев В.В. По материалам клинических рекомендаций по диагностике и лечению заболеваний щитовидной железы во время беременности и в послеродовом периоде Американской тиреоидной ассоциации. Клин. и экспер. тиреоидол. 2012; 1: 7–18.
  59. De Groot L., Abalovich M., Alexander E.K. et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2012, 97: 2543–2565.

Statistics

Views

Abstract - 756

PDF (Russian) - 1966

Cited-By


PlumX

Dimensions


Copyright (c) 2012 .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies